Exclusive | FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says
The FDA is allowing Regenxbio to resubmit its gene therapy for Hunter syndrome, marking a reversal of a previous rejection.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Regenxbio has been granted a path to resubmit its gene therapy, known as NAVSUNLI, for the treatment of Hunter syndrome (MPS II). This follows a previous rejection by the FDA regarding the childhood treatment.
Coverage from the Wall Street Journal, Endpoints News, Stat News, Stock Titan, and Seeking Alpha highlights the regulatory shift. Reports emphasize that this marks a broader trend of the FDA reconsidering previous decisions for rare-disease drugs.
Regenxbio is expected to move forward with the resubmission process for the drug. Market observers note that the company faces heightened pressure to deliver results regarding its wider pipeline, including ongoing work in Duchenne muscular dystrophy.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 148d ago.
Quick answers
What is the status of the Hunter syndrome gene therapy?
The FDA has granted Regenxbio permission to resubmit its application for NAVSUNLI following a prior rejection.
Which condition is the therapy intended to treat?
The therapy is intended for Hunter syndrome, also referred to as MPS II.
What other conditions is Regenxbio researching?
Coverage indicates the company is also working on treatments for Duchenne muscular dystrophy.
Coverage (12)
- REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II Yahoo Finance · 149d ago
- FDA reconsiders rejected rare-disease gene therapy Baton Rouge Business Report · 149d ago
- US FDA reverses course on Regenxbio's rare-disease gene therapy, backs accelerated approval bid Reuters · 149d ago
- REGENXBIO to resubmit application for Hunter gene therapy after FDA’s most recent pivot BioSpace · 149d ago
- In another reversal for rare disease field, FDA to reconsider Regenxbio gene therapy Fierce Biotech · 149d ago
- Reuters US Domestic News Summary Devdiscourse · 149d ago
- US FDA Reverses Course on Regenxbio's Rare-Disease Gene Therapy, Backs Accelerated Approval Bid U.S. News & World Report · 149d ago
- Regenxbio to resubmit Hunter syndrome gene therapy as FDA rare disease about-face continues Endpoints News · 149d ago
- REGENXBIO gets FDA path to resubmit NAVSUNLI for MPS II Stock Titan · 149d ago
- REGENXBIO’s Duchenne Data Keeps Me Bullish, But There’s Less Room For Setbacks Now (RGNX) Seeking Alpha · 149d ago
- FDA reverses course on Regenxbio’s childhood gene therapy after rejection statnews.com · 149d ago
- Exclusive | FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says WSJ · 149d ago
Topics
Related trends
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
Seawolf Therapeutics launches with $100 million from Versant Ventures and Eli Lilly to develop non-viral gene therapies targeting obesity, muscle loss, and osteoporosis.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.